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Abstract
Background: In pre-school children a diagnosis of asthma is not easily made and only a minority of wheezing
children will develop persistent atopic asthma. According to the general consensus a diagnosis of asthma becomes
more certain with increasing age. Therefore the congruence between asthma medication use and doctor-
diagnosed asthma is expected to increase with age. The aim of this study is to evaluate the relationship between
prescribing of asthma medication and doctor-diagnosed asthma in children age 0–17.
Methods: We studied all 74,580 children below 18 years of age, belonging to 95 GP practices within the second
Dutch national survey of general practice (DNSGP-2), in which GPs registered all physician-patient contacts
during the year 2001. Status on prescribing of asthma medication (at least one prescription for beta2-agonists,
inhaled corticosteroids, cromones or montelukast) and doctor-diagnosed asthma (coded according to the
International Classification of Primary Care) was determined.
Results: In total 7.5% of children received asthma medication and 4.1% had a diagnosis of asthma. Only 49% of
all children receiving asthma medication was diagnosed as an asthmatic. Subgroup analyses on age, gender and
therapy groups showed that the Positive Predictive Value (PPV) differs significantly between therapy groups only.
The likelihood of having doctor-diagnosed asthma increased when a child received combination therapy of short
acting beta2-agonists and inhaled corticosteroids (PPV = 0.64) and with the number of prescriptions (3
prescriptions or more, PPV = 0.66). Both prescribing of asthma medication and doctor-diagnosed asthma declined
with age but the congruence between the two measures did not increase with age.
Conclusion: In this study, less than half of all children receiving asthma medication had a registered diagnosis of
asthma. Detailed subgroup analyses show that a diagnosis of asthma was present in at most 66%, even in groups
of children treated intensively with asthma medication. Although age strongly influences the chance of being
treated, remarkably, the congruence between prescribing of asthma medication and doctor-diagnosed asthma
does not increase with age.
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Background
Asthma is a chronic inflammatory disease, associated with
airway hyper responsiveness that leads to recurrent epi-
sodes of wheezing, shortness of breath and chest tightness
[1]. Asthmatic complaints are relatively common in chil-
dren [1-3]. The prevalence of asthma symptoms in chil-
dren varies between global populations from less than 2%
to approximately 33% of the population [4]. In the Neth-
erlands in children from 2 to 15 years of age 4–12% expe-
rience shortness of breath and 5–20% experience chest
wheezing. About 6,5% of 7–12 year olds has asthma [5].
Around one-third of all infants have one or more wheez-
ing episodes in their first years of life [2].
There is substantial information, including guidelines, on
how children with asthma symptoms should be treated,
which kind of asthma medication should be used and
which problems should be addressed [1,6,7]. However,
studies describing actual use of asthma medication in
children show ample variability in treatment patterns
[3,8-12] and raise concern about over- and under treat-
ment both in children with and without doctor-diagnosed
asthma [8,10,11,13-16].
The interpretation of these findings differs with age of the
child. When a pre-school child with asthmatic symptoms
presents at the physician's office, a diagnosis of asthma is
not easily made [17-21]. It is well known that wheezing at
a young age may not only be due to asthma but also to
other, more transient, respiratory conditions [18-23]. Dif-
ferent wheezing phenotypes have been described in chil-
dren below the age of 6 of which transient early wheezing
is the most common one counting for over 50% of wheez-
ing children. This wheezing phenotype is often outgrown
in the first 3 years of life and only a minority of wheezing
children will develop persistent atopic asthma over time
[1,24-26]. Despite this uncertainty in diagnosis, asthma
medication is often prescribed to wheezing infants. More-
over, the response to asthma medication itself is widely
used as a diagnostic tool to strengthen or reject the possi-
ble diagnosis of asthma [1,6,7,19,22].
According to current insights and diagnostics, the diagno-
sis of asthma can be assessed more accurately with
increasing age. As can be deduced from both scientific lit-
erature and guidelines concerning treatment of children
with asthmatic symptoms [1,6,7,27], the general consen-
sus is that from the age of 5 to 6 years a diagnoses of
asthma can be made with reasonable certainty. Therefore,
theoretically, the congruence between use of asthma med-
ication and doctor-diagnosed asthma is expected to
increase with age.
However, previous studies have reported a mismatch
between asthma medication use and a diagnosis of
asthma [28-31]. Roberts et al. found that parents of 45.4%
of children aged 0 to 17 receiving asthma medication,
failed to report asthma [28]. And a study by Yeatts et al.
showed a large group of undiagnosed frequent wheezers
in children from 12 to 18 years of whom 12% used an
inhaler in the past year [30]. In most of these studies the
diagnosis of asthma was parental or self-reported, the
study was not population based, a very specific age group
was investigated or no extensive age group analysis has
been performed.
We feel that a better comprehension of the congruence
between use of asthma medication and doctor-diagnosed
asthma is useful to improve asthma medication use in
children. Therefore the aim of this study is to evaluate the
relationship between prescribing of asthma medication
and a diagnosis of asthma, as found in the GPs clinical
record, in children and adolescents aged 0–17.
Methods
Setting and study population
This study has been conducted within the framework of
the second Dutch national survey of general practice
(DNSGP-2) which was carried out in 2001 by the Nether-
lands Institute for Health Services Research (NIVEL) and
the National Institute for Public Health and the Environ-
ment (RIVM) [32,33]. The DNSGP-2 survey has been
described in detail elsewhere [32,33]. In short, 195 gen-
eral practitioners (GPs) in 104 practices, registered all
physician-patient contacts during 12 consecutive months.
The participating GPs formed a representative sample of
the total population of Dutch GPs according to age and
sex of the GP, region, and location of the practice (rural/
urban; deprived area); only the percentage of single-
handed GP practices was smaller in the DNSGP-2 study.
The total practice population consisted of 391,294
patients at the start of the survey. The population charac-
teristics corresponded very well to the Dutch population
as a whole with respect to age, sex, and the type of health
insurance.
The DNSGP-2 provides data on the nature and duration of
GP-patient contacts, disease episodes, the diagnosis
(coded using the International Classification of Primary
Care [34]), the performed actions and all prescriptions
made by the general practitioner. In the Netherlands all
non-institutionalised inhabitants are registered in a gen-
eral practice.
For the present study data from all 95 GP practices with
adequate registration of physician-patient contacts and
drug prescriptions was included. The study population
consisted of all 74,580 children below the age of 18 years
within these 95 practices.BMC Health Services Research 2008, 8:16 http://www.biomedcentral.com/1472-6963/8/16
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Measurements and analysis
Asthma medication
Prescription drugs were registered by the GP according to
the Anatomical Therapeutic Chemical (ATC) Classifica-
tion system [35]. The following of these were considered
to be asthma medication: inhaled short acting beta2-ago-
nists (SABA), oral short acting beta2-agonists, inhaled
long acting beta2-agonists (LABA), inhaled corticoster-
oids (ICS), inhaled cromones, and montelukast. All chil-
dren with at least one prescription for one of these
medicine groups in the year 2001 were included in the
study.
Asthma medication users were further subdivided into
four asthma therapy groups, which were most common in
our study population: (i) monotherapy with short acting
beta2-agonists (inhaled or oral), (ii) monotherapy with
inhaled corticosteroids, (iii) combination therapy of these
two medication groups (9.7% of the children in this
group also received one or more other asthma medicines)
and (iv) all other therapies.
To be able to differentiate between one-time asthma med-
ication users (where the medication itself might be used as
a diagnostic tool to strengthen or reject the diagnosis of
asthma) and the more chronic users we also made a sub-
division into children with (i) only one prescription, (ii)
two prescriptions and (iii) three or more prescriptions
during the study period. All medications prescribed on the
same day were considered to belong to one prescription.
Doctor-diagnosed asthma
During the study period GPs registered all contacts with
their patients, including face-to-face consultations as well
as telephone consultations and repeat prescriptions. Every
single health problem presented within a consultation
was coded by the GP using the International Classification
for Primary Care (ICPC) [34]. When a patient presented
two complaints within one consultation, these were
coded as two separate (sub)consultations. Therefore it is
known for every patient how often he or she contacted the
GP and for which health problems. GPs were trained dur-
ing an intensive course on coding practices and problems.
In this study all children who, in the year under study,
contacted the GP with a health problem subsequently
coded as ICPC R96 (asthma) were considered to have doc-
tor-diagnosed asthma.
Data analysis
To quantify the congruence between prescription of
asthma medication and doctor-diagnosed asthma we
determined Sensitivity and Positive Predictive Value
(PPV) of asthma medication use as a predictor for doctor-
diagnosed asthma. Based on the general consensus that
from the age of 5 to 6 years a diagnosis of asthma can be
made with reasonable certainty we divided the study pop-
ulation into two age groups: children below the age of 6
and children aged 6 years and older and analysed whether
the found congruence changes. We repeated these analy-
ses in subgroups of age, gender, asthma therapy and
number of prescriptions. We also performed these analy-
ses increasing the cut-off point for defining 'asthma med-
ication use' from 1 to a minimum of 2 prescriptions, this
way excluding possible trial medication. The results from
these analyses are added as online repository material (see
additional file 1).
Statistical analyses were performed using SAS, version 9.1
(SAS Institute, Cary, NC).
Results
General characteristics of the study population are pre-
sented in Table 1. The study population was similar to the
Dutch population with respect to gender and age groups.
Prescription of asthma medication within our study pop-
ulation was 7.5% in the year 2001. In the same episode a
diagnosis of asthma was present in the GPs' clinical record
for 4.1% of the study population. Thus prescribing of
asthma medication was twice as common as doctor-diag-
nosed asthma.
An overview of the applied therapies, stratified by age
groups is presented in Table 2. We see that prescription of
asthma medication changed with age. The prescribing of
asthma medication was highest in children age 0–2 years
(11.7%) and steadily declined with rising age, to 5.1% in
the group of 15–17 year old children. Although differ-
ences could be observed in the applied therapies, there
were no obvious trends with age. Monotherapy with
inhaled short acting beta2-agonist and the combination
of this drug with inhaled corticosteroids were the most
applied therapies in all age groups. Of all children receiv-
ing asthma medication 52.9% received medication on
only one occasion.
In Figure 1 we plotted the course of prescribing of asthma
medication and doctor-diagnosed asthma with age. We
found that both prescribing of asthma medication and
doctor-diagnosed asthma declined with age. Initially pre-
scribing of asthma medication seems to decline more rap-
idly with age than a diagnosis of asthma. Taking into
account only the first 3 age groups one would expect the
lines of prescribing and diagnosis to eventually cross each
other. However, after age 6–8 the lines run virtually paral-
lel, thus the gap between prescribing and diagnosing does
not resolve. Moreover, approximately twice as many chil-
dren received asthma medication than a diagnosis of
asthma both in age group 0–2 and in age group 15–17.BMC Health Services Research 2008, 8:16 http://www.biomedcentral.com/1472-6963/8/16
Page 4 of 9
(page number not for citation purposes)
Table 1: Patient characteristics of the study population
Total study population 
(74,580)
Asthma medication users 
(5,605)
Children with doctor-diagnosed 
asthma (3,064)
N%N% N %
Gender
Male 38,267 51.3 3,160 56.4 1,775 57.9
Female 36,313 48.7 2,445 43.6 1,289 42.1
Age (years)
0–2 9,030 12.1 1053 18.8 540 17.6
3–5 12,690 17.0 1300 23.2 689 22.5
6–8 13,357 17.9 1004 17.9 589 19.2
9–11 13,521 18.1 853 15.2 490 16.0
12–14 13,087 17.6 738 13.2 445 14.5
15–17 12,895 17.3 657 11.7 311 10.2
Other respiratory problems
shortness of breath 367 0.5 240 4.3 101 3.3
wheezing 176 0.2 144 2.6 46 1.5
acute URTI* 6307 8.5 1122 20.0 530 17.3
acute bronchitis/bronchiolitis 2269 3.0 1002 17.9 406 13.3
pneumonia 679 0.9 254 4.5 129 4.2
allergic rhinitis 1983 2.7 394 7.0 223 7.3
Number of contacts with GP
0 22784 30.5 240 4.3 0 0
1–2 26725 35.8 1314 23.4 658 21.5
≥3 25071 33.6 4051 72.3 2406 78.5
Oral corticosteroid use 337 0.5 188 3.4 143 4.7
At least 1 parent with doctor-
diagnosed asthma^
3106 4.3 483 8.9 312 10.5
* URTI = Upper Respiratory Tract Infection
^ Based on data from 96% of the study population due to missing values (N = 71712)
Table 2: Prescription of asthma medication by age group and type of medication
Age groups
0–2 3–5 6–8 9–11 12–14 15–17 Total
n = 9,030 n = 12,690 n = 13,357 n = 13,521 n = 13,087 n = 12,895 n = 74,580
Prescription of asthma medication 11.7 10.2 7.5 6.3 5.6 5.1 7.5
Therapy groups, %
SABA 36.9 24.9 28.0 32.2 40.4 40.5 32.7
ICS 19.5 22.9 23.1 20.5 16.3 19.6 20.7
SABA + ICS 35.0 45.3 43.4 40.0 36.7 30.9 39.4
Other medicines 8.6 7.0 5.5 7.3 6.6 9.0 7.2
1 prescription 58.1 52.5 48.3 52.3 52.6 53.7 52.9
2 prescriptions 20.2 21.1 21.9 21.0 19.7 20.2 20.8
≥3 prescriptions 21.7 26.5 29.8 26.7 27.8 26.0 26.3
SABA = short acting beta2-agonists; ICS = inhaled corticosteroidsBMC Health Services Research 2008, 8:16 http://www.biomedcentral.com/1472-6963/8/16
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The congruence between prescribing of asthma medica-
tion and doctor-diagnosed asthma for the overall study
population is shown in two ways in Figure 2. The sensitiv-
ity shows that when selecting all asthma medication users,
89% of children with doctor-diagnosed asthma would be
included in this selection. In other words, almost all chil-
dren with doctor-diagnosed asthma were prescribed
asthma medication. On the other hand, indicated by a
PPV of 0.49, when selecting a child with asthma medica-
tion, this child would have doctor-diagnosed asthma in
only 49% of the cases. Children receiving asthma medica-
tion without having doctor-diagnosed asthma had a regis-
tered diagnosis for other respiratory diseases (including
acute upper respiratory infections, acute bronchitis, bron-
chiolitis and allergic rhinitis) or only a complaints diag-
nosis (including dyspnoea, wheezing and cough) during
the registration period in respectively 45.4% and 21.9% of
the cases.
Based on the general consensus that from the age of 5 to
6 years a diagnosis of asthma can be made with reasona-
ble clinical certainty, we divided the study population
into two age groups: children below the age of 6 and chil-
dren aged 6 years and older. In Figure 2 we showed that
there is an obvious age difference with respect to the
number of children treated with asthma medication and
diagnosed as being asthmatics. However, the congruence
between these two measures does not differ between
younger (<6) and older children (≥6). Below 6 years of
age 46% of the treated children had a diagnosis of asthma
and in the older age group this was 51%.
Further subgroup analyses are shown in Table 3. Boys
were more often treated with asthma medication and
diagnosed with asthma than girls, but the PPV and sensi-
tivity were similar. Between medication groups the PPV
differed significantly: children on combination therapy
were more likely to have doctor-diagnosed asthma. Also
children who received asthma medication on more than
one occasion had a greater chance of being diagnosed as
asthmatics, with a PPV rising from 0.38 for children with
one prescription to 0.66 for children with at least three
prescriptions. The results from the analyses after changing
our cut-off point for defining 'asthma medication use'
from 1 to a minimum of 2 prescriptions are added as
online repository material (see additional file 1).
The course of prescription of asthma medication and doctor- diagnosed asthma with age Figure 1
The course of prescription of asthma medication and doctor-
diagnosed asthma with age.
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Looking at gender differences we found that the difference
between boys and girls lies mainly in the number of chil-
dren treated with combination therapy and diagnosed
with asthma (both higher in boys) but not in congruence
between medication and diagnosis. Only the PPVs of ICS
use only and of one prescription only were slightly higher
in boys (0.45 and 0.40 respectively) than in girls (0.38
and 0.35 respectively).
Within the two age classes (<6 years and ≥6 years) sepa-
rately, again no major differences in congruence were
found between subgroups of gender, asthma therapy and
number of prescriptions. The results for the older age
group separately are added as online repository material
(see additional file 2). The sensitivity remained high
throughout the entire analyses, children with an asthma
diagnosis received asthma medication in 87–91% of the
cases. In children below the age of 6 gender differences
were more pronounced. Girls this age were treated less
than boys (4.5% versus 6.7%) and when treated, they
were less likely to get diagnosed with asthma (PPV of 0.42
versus 0.49). In the older age group these gender differ-
ences were not present, 3.2% of girls was treated and 3.8%
of boys and the PPVs were 0.50 and 0.51 respectively. This
also shows that in boys the PPV was the same in both age
groups (0.51) whereas this differed for girls (PPV 0.42 for
girls <6 and 0.50 for girls ≥6). The lowest overall PPV
found was for girls below 6 years of age. Within this group
58% of children with asthma medication did not have
doctor-diagnosed asthma.
Discussion
The congruence between asthma medication use and doc-
tor-diagnosed asthma can be considered from two angles.
One way is to determine whether all children with a diag-
nosis of asthma receive treatment. In our study an overall
high sensitivity of 0.89 shows that indeed a high percent-
age of children diagnosed with asthma receive asthma
medication. The other way, investigating whether chil-
dren using asthma medication have an asthma diagnosis,
we find that overall only 49% of all children receiving
asthma medication has doctor-diagnosed asthma (i.e.,
2,868 children receive asthma medication without a diag-
nosis of asthma). This discrepancy could be due to many
factors, including over treatment, off-label use, under
diagnosis and use of asthma medication as a diagnostic
tool.
We hypothesised that the congruence between prescrip-
tion of asthma medication and doctor-diagnosed asthma
would increase with age. We expected to find more undi-
agnosed children and children with one prescription only
in children using asthma medication below the age of 6,
because of diagnostic difficulties at this age and the use of
medication as a diagnostic tool. Most children who
wheeze at this age suffer from transient or self-limiting
disease and might receive medication to lessen com-
plaints but do not receive the label 'asthma'. From age 6
the diagnosis of asthma can be made with more certainty
and the children receiving asthma medication are
expected to be the 'real asthmatics' and thus have a match-
ing diagnosis of asthma. We find that indeed both pre-
scribing of asthma medication and doctor-diagnosed
asthma are influenced by age. However, they both decline
with rising age and the high sensitivity and low positive
predictive value (PPV) found in the overall study popula-
tion was consistent throughout the different age groups.
Table 3: Subgroup analysis of the congruence between prescription of asthma medication and doctor-diagnosed asthma.
N Asthma medication use, % Doctor-diagnosed asthma, % PPV* Sensitivity
Total population 74,580 7.5 4.1 0.49 0.89
Male 38,267 8.3 4.6 0.50 0.89
Female 36,312 6.7 3.5 0.47 0.90
<6 yrs 21,720 10.8 5.7 0.46 0.88
≥6 yrs 52,860 6.2 3.5 0.51 0.90
SABA only 2.5 4.1 0.38 ^
ICS only 1.6 4.1 0.42
SABA + ICS 3.0 4.1 0.64
1 prescription 4.0 4.1 0.38 ^
2 prescriptions 1.6 4.1 0.54
≥3 prescriptions 2.0 4.1 0.66
* All Pearson's Chi-Square p-values < .0001
^ The sensitivities for subgroups of asthma medication users are not shown, since they are highly dependent on the percentual contribution of the 
subgroups to the total group of asthma medication users and are therefore not very informative and, by definition, low.BMC Health Services Research 2008, 8:16 http://www.biomedcentral.com/1472-6963/8/16
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In subgroup analyses on gender and age we found only
minor differences in PPV. The largest difference is between
young girls (<6 years) and older girls (≥6) with 42% ver-
sus 50% receiving treatment without a diagnosis of
asthma.
The PPV differs significantly between subgroups of ther-
apy. Children on combination therapy have a much
higher chance of having doctor-diagnosed asthma (PPV
0.64) than do children using short-acting beta2-agonists
only (PPV 0.38). Also the number of prescriptions for
asthma medication strongly influences the relationship
with doctor-diagnosed asthma. However, the PPV never
comes close to 1, thus no matter which subgroup you
select, there is always a substantial number of children
present that is treated with asthma medication without
being diagnosed as an asthmatic.
The number of children using asthma medication and the
declining trend with age found in our study is consistent
with results from other studies [11,36] as is the number of
children with doctor-diagnosed asthma[37].
Recent guidelines state that the first 2 treatment steps to
manage asthma for children age 6 and older are the fol-
lowing: start with inhaled short acting beta2-agonists
(SABA) as needed and add a low-dose inhaled corticoster-
oids (ICS) when symptoms are more frequent and/or
worsen periodically. And although the evidence is not as
strong in children age 5 years and younger, which pre-
cludes detailed treatment recommendations, these same 2
initial steps are recommended for this age group [1,6,7].
For the major part the therapies applied in our study pop-
ulation seem to be in line with these guidelines. However,
there is quite a large group of children receiving ICS with-
out receiving a prescription for SABA in that same year.
This could indicate that there is some overtreatment with
ICS. Another explanation could be that children had very
little need for reliever medication and still used SABA dis-
pensed in the previous year. Indeed, although the guide-
lines state that reliever medication should always be
provided for quick relief of symptoms, reducing or elimi-
nating the need for reliever treatment is both an impor-
tant goal and a measure of success of treatment [1].
Our finding that 89% of children diagnosed with asthma
receive asthma medication differs from other studies, in
which many children with a diagnosis of asthma did not
receive medication (ranging from 21.8 to 64.4%)
[12,28,30,31]. However, these studies used parental-
reported doctor-diagnosed asthma from questionnaire
data, which have been shown to differ substantially from
a diagnosis of asthma derived from the GPs clinical
records in the sense that self-reported asthma renders
many more 'asthmatics' than do the GP's records [38].
Despite this higher number of 'asthmatics' these studies
do show similar results with respect to the percentage of
children being treated without an asthma diagnosis. This
percentage is lower than our finding (20.9%) in only one
study, but comparable, ranging from 40.0% to 47.3%, in
the other four studies [3,12,28,31,39]. One previous
study used medical and pharmacy claim data instead of
questionnaire data and found that children receiving
asthma medication without a diagnosis of asthma have
considerable morbidity and health care utilisation. The
authors conclude that better recognition of paediatric
asthma is warranted [29]. Although this study was not
population based (but made use of an administrative
claims based dataset) and mainly focuses on the eco-
nomic impact of undiagnosed children dispensed asthma
medication, without detailed subgroup analyses, their
finding that 40% of children used asthma medication
without evidence of a documented doctor-diagnosed
claim for asthma is in line with our own findings.
The current study has some limitations. First, we do not
have information on specialist care. In the hypothetical
case that a GP continues asthma medication initiated by a
specialist without registering the diagnosis this would add
to the group of children being treated without a diagnosis
of asthma. However, very few children in our study popu-
lation were referred to a child lung physician (0.4% of
children using asthma medication) or even to a paediatri-
cian in general (5.4% of children using asthma medica-
tion). Second, in this study asthma diagnoses as registered
by the GP are taken into account, and although often used
as a gold standard in studies, this might not be the true
reflection of asthmatics in the study population. Third,
some overestimation of medication use might be present
since not all prescribed medication is filled in the phar-
macy. Since our interest lies in the relationship between
the two GP based actions of diagnosing and prescribing
(Does the GP base prescribing of medication on his deci-
sion whether or not to diagnose a child with asthma?),
these last two limitations are of only relative importance
to our study.
Conclusion
Several conclusions can be drawn from the work pre-
sented here. Firstly, less than half of all children pre-
scribed asthma medication had a registered diagnosis of
asthma. Secondly, detailed subgroup analyses show that a
diagnosis of asthma is present in at most 66% of children;
even in children treated extensively with asthma medica-
tion, such as children prescribed inhaled corticosteroids
or receiving asthma medication on at least three occasions
within one year. Lastly, although age strongly influences
the chance of being treated, remarkably, the congruence
between prescribing of asthma medication and doctor-
diagnosed asthma does not improve with age. FurtherBMC Health Services Research 2008, 8:16 http://www.biomedcentral.com/1472-6963/8/16
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research is needed to determine what causes this discrep-
ancy and whether this is grounds for changing asthma
medication use in children.
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